|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
86618 JD HEALTH-R
Nominal 
33.980 0.000 (0.000%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 40,887,884 | 15.862% | 73,441,487 | 58,159,881 | 53,529,941 | 46,736,150 |
| Cost of Sales | (30,201,891) | 14.409% | (55,242,325) | (44,851,304) | (41,664,605) | (36,844,642) |
| Gross Profit | 10,685,993 | 20.176% | 18,199,162 | 13,308,577 | 11,865,336 | 9,891,508 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 10,738 | -- | (142,786) | (315,853) | (69,859) | (98,202) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (33,809) | -13.636% | (64,050) | (85,527) | (70,757) | (96,759) | |
| Profit / (Loss) before Taxation | 4,250,776 | 48.438% | 6,029,995 | 4,796,676 | 2,693,348 | 695,809 | |
| Taxation | (815,368) | 199.416% | (662,886) | (639,662) | (550,468) | (312,580) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 1,396 | -72.617% | 8,296 | 4,830 | (1,039) | (3,124) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,436,804 | 32.366% | 5,375,405 | 4,161,844 | 2,141,841 | 380,105 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (627,265) | -22.020% | (1,526,436) | (1,952,308) | (1,939,547) | (855,167) |
| Depreciation & Amortisation | 183,909 | 52.816% | 279,989 | 214,695 | 227,458 | 140,676 |
| Directors' Emoluments | -- | -- | -- | 276,896 | 418,439 | 664,846 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 108.000 | 31.707% | 170.000 | 132.000 | 69.000 | 12.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 3.216 | 1.379 | 1.474 | 1.901 |
| NBV per share ($) | 19.139 | -- | 18.718 | 17.267 | 15.479 | 14.082 |
| Remarks: | Real time quote last updated: 14/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,436,804 |
| %Change | 32.366% |
| EPS / (LPS) | RMB 1.080 |
| NBV Per Share (¥) | RMB 19.139 |